Regeneron Pharmaceuticals - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Regeneron Pharmaceuticals
REGN
|
NASDAQ
|
United States
235
-107
Rank
$115.11B
Market Cap
$14.20B
+$ 1.09B
+8.31%
Revenue
$4.77B
+$ 0.12B
+2.58%
Earnings
15.2K
+1.7K
+12.7%
Employees
About
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $769
07.07.2026 -
This Meta Platforms Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
07.07.2026 -
Benchmark Upgrades Regeneron Pharmaceuticals to Buy, Announces $185 Price Target
07.07.2026 -
Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth
03.07.2026 -
Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme
30.06.2026